Matches in Wikidata for { <http://www.wikidata.org/entity/Q74277173> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q74277173 description "clinical trial" @default.
- Q74277173 description "ensayu clínicu" @default.
- Q74277173 description "klinisch onderzoek" @default.
- Q74277173 description "клінічне випробування" @default.
- Q74277173 name "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 name "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 type Item @default.
- Q74277173 label "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 label "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 prefLabel "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 prefLabel "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 P1132 Q74277173-986864A2-E439-402B-9EFC-4EE248083D24 @default.
- Q74277173 P1476 Q74277173-417410A9-FDD3-45E4-9D3F-97B1AFE9BF68 @default.
- Q74277173 P17 Q74277173-439E1CD1-C255-408C-B76C-4A11C956E032 @default.
- Q74277173 P2899 Q74277173-D293F969-CC90-4735-B23E-4E915BE0EBA0 @default.
- Q74277173 P3098 Q74277173-10BD7524-754D-44E8-90D3-BEF9C3AA57D7 @default.
- Q74277173 P31 Q74277173-9FF7A688-4762-4B1F-A2B6-D84C9775C415 @default.
- Q74277173 P4135 Q74277173-4B834E57-E075-4320-A401-366A05591FC0 @default.
- Q74277173 P580 Q74277173-4B26CEE8-DA5E-4F8F-8E0A-03575F55E100 @default.
- Q74277173 P582 Q74277173-EBAA61F6-F149-4C38-9CBE-BA222FDF14DC @default.
- Q74277173 P6099 Q74277173-63691B6B-96DA-4455-882F-442D8EAC09EE @default.
- Q74277173 P8363 Q74277173-B3DA00A7-64CF-499D-A255-950BE36448AF @default.
- Q74277173 P1132 "+24" @default.
- Q74277173 P1476 "A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients" @default.
- Q74277173 P17 Q865 @default.
- Q74277173 P2899 "+20" @default.
- Q74277173 P3098 "NCT04115761" @default.
- Q74277173 P31 Q30612 @default.
- Q74277173 P4135 "+75" @default.
- Q74277173 P580 "2019-06-06T00:00:00Z" @default.
- Q74277173 P582 "2021-12-31T00:00:00Z" @default.
- Q74277173 P6099 Q42824440 @default.
- Q74277173 P8363 Q78089383 @default.